Table of Contents
PRINCETON, N.J. — Sandoz has introduced in the United States its first-to-file calcipotriene cream (.005%), a topical medication for psoriasis.
The company said Friday that its product marks the first generic version of LEO Pharma Inc.’s Dovonex Cream (.005%) in the United States.
Calcipotriene cream is indicated for the treatment of plaque psoriasis.
"Sandoz is proud to be both the first company to file for and the first to launch this important new generic dermatology medicine, which further strengthens Sandoz’s No. 1 position in generic dermatology medicines in the U.S. and globally," stated Don DeGolyer, president of Sandoz US. "The launch of calcipotriene cream further demonstrates our commitment to improving patient access to high-quality, affordable medicines."
U.S. sales for the branded version of calcipotriene cream were about $118.8 million for the 12 months ended in May, according to IMS Health figures reported by Sandoz.
